A fludarabine-based conditioning regimen for severe aplastic anemia

被引:35
作者
Chan, KW
Li, CK
Worth, LL
Chik, KW
Jeha, S
Shing, MK
Yuen, PM
机构
[1] Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China
关键词
severe aplastic anemia; fludarabine; alternative donors; allogeneic stem cell transplantation;
D O I
10.1038/sj.bmt.1702768
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Graft rejection is a common problem after alternative donor transplantation for patients with refractory severe aplastic anemia (SAA). Intensification of the conditioning regimen, with the inclusion of irradiation, has often been advocated to combat this problem. With this approach engraftment rate improved, but the incidence of transplant-related complications is also increased, resulting in little change in the overall outcome. We investigated the use of the combination of fludarabine, cyclophosphamide and anti-thymocyte globulin as the conditioning regimen in five multiply-transfused SAA patients. Three patients received an HLA one-antigen disparate related donor transplant, while two patients were given marrow from matched, unrelated donors. The regimen was well tolerated, with only grade I toxicity encountered. With a median follow-up of 9 months, all patients are alive with complete donor chimerism, We conclude that fludarabine may be used in place of irradiation to augment the conditioning regimen of cyclophosphamide and anti-thymocyte globulin for alternative donor transplantation in children with SAA.
引用
收藏
页码:125 / 128
页数:4
相关论文
共 21 条
  • [1] ABELLA E, 1999, P IBMTR ASBMT M, P44
  • [2] Treatment of acquired severe aplastic anemia:: Bone marrow transplantation compared with immunosuppressive therapy -: The European Group for Blood and Marrow Transplantation Experience
    Bacigalupo, A
    Brand, R
    Oneto, R
    Bruno, B
    Socié, G
    Passweg, J
    Locasciulli, A
    Van Lint, MT
    Tichelli, A
    McCann, S
    Marsh, J
    Ljungman, P
    Hows, J
    Marin, P
    Schrezenmeier, H
    [J]. SEMINARS IN HEMATOLOGY, 2000, 37 (01) : 69 - 80
  • [3] Bacigalupo A, 1997, INT J PEDIAT HEM ONC, V4, P267
  • [4] Bacigalupo A, 1999, BONE MARROW TRANSPL, V23, pS70
  • [5] REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    BEARMAN, SI
    APPELBAUM, FR
    BUCKNER, CD
    PETERSEN, FB
    FISHER, LD
    CLIFT, RA
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1562 - 1568
  • [6] CHAMPLIN RE, 1989, BLOOD, V73, P606
  • [7] Deeg H J, 1999, Biol Blood Marrow Transplant, V5, P243, DOI 10.1053/bbmt.1999.v5.pm10465104
  • [8] Deeg H. J., 1997, Blood, V90, p397A
  • [9] DEEG HJ, 1994, BLOOD, V83, P3417
  • [10] Deeg HJ, 1999, BLOOD, V94, p713A